title: Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome.
authors.forename: Nicola
authors.initials: N
authors.lastname: Gianotti
authors.forename: Alessandro
authors.initials: A
authors.lastname: Soria
authors.forename: Laura
authors.initials: L
authors.lastname: Galli
authors.forename: Barbara
authors.initials: B
authors.lastname: Giudici
authors.forename: Giuliana
authors.initials: G
authors.lastname: Fusetti
authors.forename: Adriano
authors.initials: A
authors.lastname: Lazzarin
authors.forename: Enzo
authors.initials: E
authors.lastname: Boeri
authors.forename: Antonella
authors.initials: A
authors.lastname: Castagna
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D024921:Drug Resistance, Multiple, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D016014:Linear Models; D016896:Treatment Outcome
chemical_list: D017320:HIV Protease Inhibitors